Breaking News Instant updates and real-time market news.

MDCO

The Medicines Co.

$42.56

-0.83 (-1.91%)

17:12
05/19/17
05/19
17:12
05/19/17
17:12

Court preliminarily approves settlement in The Medicines Co.'s cangrelor case

On May 12, the United States District Court for the District of New Jersey issued an order preliminarily approving a proposed settlement by and among The Medicines Company, the plaintiffs, and all named individual defendants in the shareholder derivative action Case No. 2:17-cv-01597 related to the company's clinical trial of cangrelor. The proposed settlement requires the company to implement certain corporate governance measures and pay certain attorneys' fees and expenses to plaintiff's counsel in an amount to be determined by the court. A hearing to determine whether the court should issue an order of final approval of the settlement has been scheduled for September 21, 2017 at 10:30 a.m. in Courtroom MLK 5B of the United States District Court for the District of New Jersey, Martin Luther King Building & United States Courthouse, 50 Walnut Street, Newark, New Jersey 07101 to determine whether the terms and conditions of the settlement are adequate, fair and reasonable. Pursuant to the court's order, any objections to the settlement must be filed in writing with the court by no later than August 17, 2017.

  • 22

    May

  • 06

    Jun

MDCO The Medicines Co.
$42.56

-0.83 (-1.91%)

03/17/17
JPMS
03/17/17
NO CHANGE
JPMS
Overweight
Amgen data do not justify Medicines selloff, says JPMorgan
JPMorgan analyst Jessica Fye believes today's cholesterol data from Amgen (AMGN) do not justify the downward move in shares of The Medicines Co. (MDCO). The analyst sees a "clear clinical benefit" from Amgen's Repatha, which she thinks support the likelihood of clinical success and value for Medicines' inclisiran. The analyst remains comfortable with her 70% probability of success and $1.6B peak sales forecast for inclisiran. Fye keeps an Overweight rating on Medicines and believes the 18% selloff today is overdone.
04/13/17
JEFF
04/13/17
NO CHANGE
Target $62
JEFF
Buy
Medicines Co. open to spinoff of infectious disease unit, says Jefferies
After spending time with management as the company evaluates all strategic options including a sale, Jefferies analyst Biren Amin says The Medicines Company believes there is more than one form for a takeover. In addition to the entire organization potentially being acquired, management spoke of a scenario whereby an acquirer may not want the infectious disease business, Amin telsl investors in a research note. Under such a case, the company would be prepared to spin-off as a standalone organization upon a sale of inclisiran, the analyst adds. He believes this option leaves room to negotiate on the value of inclisiran versus simply paying a premium over the current share price. Amin keeps a Buy rating on Medicines Co. with a $62 price target.
04/19/17
COWN
04/19/17
NO CHANGE
Target $61
COWN
Outperform
The Medicines Co. price target raised to $61 from $39 at Cowen
Cowen analyst Chris Shibutani raised his price target on The Medicines Company to $61 from $39 following a cardiologist survey suggesting the company's Inclisiran will contend for patient share assuming pivotal data demonstrates similar safety and efficacy to monoclonal antibodies. Shibutani reiterated his Outperform rating on The Medicines Company shares.
04/21/17
JEFF
04/21/17
NO CHANGE
Target $62
JEFF
Buy
The Medicines Co. suggesting several parties interested in deal, says Jefferies
Jefferies analyst Biren Amin said feedback he's received from management at The Medicines Co. suggests that talks about the company's strategic process began in January and that there are "several interested parties" involved. Management added that they will stay open to discussions until "significant" patient enrollment has occurred in their Phase 3 trail, Amin added. The analyst, who thinks a 13-15 month timeframe is a reasonable one to expect for the process to come to a conclusion, keeps a Buy rating and $62 price target on Medicines Co. shares.

TODAY'S FREE FLY STORIES

IP

International Paper

$58.25

0.04 (0.07%)

07:22
10/24/17
10/24
07:22
10/24/17
07:22
Initiation
International Paper initiated  »

International Paper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

GLW

Corning

$30.01

-0.05 (-0.17%)

07:22
10/24/17
10/24
07:22
10/24/17
07:22
Technical Analysis
Technical View: Corning ticks higher after beating consensus expectations »

Shares were last up 0.8%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

WRK

WestRock

$60.76

0.23 (0.38%)

07:21
10/24/17
10/24
07:21
10/24/17
07:21
Initiation
WestRock initiated  »

WestRock initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

WHR

Whirlpool

$182.50

0.04 (0.02%)

07:20
10/24/17
10/24
07:20
10/24/17
07:20
Technical Analysis
Technical View: Whirlpool down sharply as results, view, miss expectations »

The stock is set to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 14

    Nov

07:20
10/24/17
10/24
07:20
10/24/17
07:20
General news
FX Update: The dollar has traded firmer »

FX Update: The dollar has…

GLW

Corning

$30.01

-0.05 (-0.17%)

07:19
10/24/17
10/24
07:19
10/24/17
07:19
Hot Stocks
Corning sees every business segment to meet or beat plan in Q4 »

"Year-to-date…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

HNI

HNI Corporation

$42.29

-0.57 (-1.33%)

07:19
10/24/17
10/24
07:19
10/24/17
07:19
Downgrade
HNI Corporation rating change  »

HNI Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

PTCT

PTC Therapeutics

$16.99

-0.8 (-4.50%)

07:19
10/24/17
10/24
07:19
10/24/17
07:19
Conference/Events
Breaking Conference/Events news story on PTC Therapeutics »

FDA PDUFA Date for PTC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 02

    Nov

  • 06

    Nov

GLW

Corning

$30.01

-0.05 (-0.17%)

07:18
10/24/17
10/24
07:18
10/24/17
07:18
Earnings
Corning reports Q3 core EPS 43c, consensus 41c »

Reports Q3 GAAP revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

HYGS

Hydrogenics

07:16
10/24/17
10/24
07:16
10/24/17
07:16
Conference/Events
TMX Group to hold a conference »

TSX Industrial &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 06

    Nov

  • 16

    Nov

THR

Thermon Group

$21.40

0.4 (1.90%)

07:16
10/24/17
10/24
07:16
10/24/17
07:16
Recommendations
Thermon Group analyst commentary  »

Thermon Group price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEGA

Pegasystems

$59.15

-0.3 (-0.50%)

07:16
10/24/17
10/24
07:16
10/24/17
07:16
Recommendations
Pegasystems analyst commentary  »

Pegasystems should be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHW

Sherwin-Williams

$386.58

-3.12 (-0.80%)

07:16
10/24/17
10/24
07:16
10/24/17
07:16
Technical Analysis
Technical View: Sherwin-Williams slips lower after results »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 30

    Oct

ELVT

Elevate Credit

$7.52

-0.14 (-1.83%)

, FPAY

FlexShopper

07:15
10/24/17
10/24
07:15
10/24/17
07:15
Conference/Events
Stephens to hold meetings at conference »

Stephens Hosted Company…

ELVT

Elevate Credit

$7.52

-0.14 (-1.83%)

FPAY

FlexShopper

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 30

    Oct

CTMX

CytomX Therapeutics

$20.04

-0.12 (-0.60%)

07:15
10/24/17
10/24
07:15
10/24/17
07:15
Initiation
CytomX Therapeutics initiated  »

CytomX Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$171.27

-3.71 (-2.12%)

07:15
10/24/17
10/24
07:15
10/24/17
07:15
Periodicals
Facebook faces EU-wide privacy fights after top court setback, Bloomberg says »

Facebook may faces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 01

    Nov

  • 08

    Nov

  • 15

    Nov

HFC

HollyFrontier

07:15
10/24/17
10/24
07:15
10/24/17
07:15
Downgrade
HollyFrontier rating change  »

HollyFrontier downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

PBF

PBF Energy

07:15
10/24/17
10/24
07:15
10/24/17
07:15
Downgrade
PBF Energy rating change  »

PBF Energy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPX

Louisiana-Pacific

07:15
10/24/17
10/24
07:15
10/24/17
07:15
Initiation
Louisiana-Pacific initiated  »

Louisiana-Pacific…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

VLO

Valero

07:14
10/24/17
10/24
07:14
10/24/17
07:14
Downgrade
Valero rating change  »

Valero downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

DK

Delek US

07:14
10/24/17
10/24
07:14
10/24/17
07:14
Upgrade
Delek US rating change  »

Delek US upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

ALDW

Alon USA Partners

$11.74

0.05 (0.43%)

07:14
10/24/17
10/24
07:14
10/24/17
07:14
Upgrade
Alon USA Partners rating change  »

Alon USA Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

07:13
10/24/17
10/24
07:13
10/24/17
07:13
Conference/Events
Drug Information Association to hold a conference »

Biosimilars Conference is…

PEBO

Peoples Bancorp

$33.03

-0.79 (-2.34%)

07:13
10/24/17
10/24
07:13
10/24/17
07:13
Earnings
Peoples Bancorp reports Q3 EPS 60c, consensus 50c »

Reports Q3 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

WY

Weyerhaeuser

$34.82

-0.46 (-1.30%)

07:13
10/24/17
10/24
07:13
10/24/17
07:13
Initiation
Weyerhaeuser initiated  »

Weyerhaeuser initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.